Guardant Health CLO now holds 56,903 shares

Guardant Health, Inc. Chief Legal Officer John G. Saia reported equity awards vesting and converting into common stock on March 15, 2026.

Rhea-AI Filing Summary

Guardant Health, Inc. Chief Legal Officer John G. Saia reported equity awards vesting and converting into common stock on March 15, 2026. Performance-based and time-based restricted stock units were exercised under code “M,” delivering additional Guardant Health common shares.

The company retained 4,622 shares at $85.49 per share under code “F” to satisfy Mr. Saia’s tax withholding obligations, as described in the footnotes. After these transactions, he directly owns 56,903 shares of Guardant Health common stock.

Insider Trade Summary

8,811 shares exercised/converted

Exercise 5 txns

Insider Saia John G.

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Exercise	Performance-Based Restricted Stock Units	7,792	$0.00	$0.00
Exercise	Restricted Stock Units	1,019	$0.00	$0.00
Exercise	Common Stock	7,792	$0.00	$0.00
Exercise	Common Stock	1,019	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	4,622	$85.49	$395K

Holdings After Transaction: Performance-Based Restricted Stock Units — 0 contracts (Direct); Restricted Stock Units — 1,020 contracts (Direct); Common Stock — 56,903 shares (Direct)

Footnotes (4)

1. F1. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
2. F2. This represents a performance-based restricted stock unit award granted on June 7, 2023 with a 3-year performance metric. The second tranche metric was achieved and the shares vested on March 15, 2026.
3. F3. Not applicable for Restricted Stock Units.
4. F4. This represents a restricted stock unit award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 15, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Guardant Health (GH) insider John G. Saia report on this Form 4?

John G. Saia, Chief Legal Officer of Guardant Health, reported vesting and conversion of performance-based and time-based restricted stock units into common stock. The transactions were classified as derivative exercises (code “M”) and a tax-withholding share disposition (code “F”), not open-market purchases or sales.

How many Guardant Health shares does John G. Saia own after the reported transactions?

Following the March 15, 2026 equity vesting and related tax-withholding transaction, John G. Saia directly owns 56,903 shares of Guardant Health common stock. This figure reflects the net position after RSU conversions into common stock and the company’s retention of shares to cover tax obligations.

What equity awards vested for Guardant Health insider John G. Saia on March 15, 2026?

A performance-based restricted stock unit award granted June 7, 2023 vested its second tranche after meeting a three-year performance metric, and a separate RSU award granted June 9, 2023 continued its scheduled vesting. Both awards converted into Guardant Health common stock on March 15, 2026.

Why were 4,622 Guardant Health shares withheld in John G. Saia’s Form 4?

Guardant Health retained 4,622 shares at $85.49 per share to meet John G. Saia’s tax withholding obligations tied to the RSU vesting. Footnotes clarify the amount withheld did not exceed the tax liability and represents a tax-payment mechanism rather than an open-market stock sale.

Did John G. Saia buy or sell Guardant Health (GH) stock on the open market?

The filing shows no open-market purchase or sale. All transactions are coded as derivative exercises (M) converting restricted stock units into common stock and a tax-withholding disposition (F), where shares were retained by Guardant Health to cover withholding obligations instead of being traded in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 06:49 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saia John G.

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/15/2026		M		7,792	A	$0	60,506	D
Common Stock	03/15/2026		M		1,019	A	$0	61,525	D
Common Stock	03/15/2026		F		4,622(1)	D	$85.49	56,903	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance-Based Restricted Stock Units	$0	03/15/2026		M			7,792	(2)	(3)	Common Stock	7,792	$0	0	D
Restricted Stock Units	$0	03/15/2026		M			1,019	(4)	(3)	Common Stock	1,019	$0	1,020	D

Explanation of Responses:

1. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.

2. This represents a performance-based restricted stock unit award granted on June 7, 2023 with a 3-year performance metric. The second tranche metric was achieved and the shares vested on March 15, 2026.

3. Not applicable for Restricted Stock Units.

4. This represents a restricted stock unit award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 15, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

Remarks:

	/s/ John G. Saia	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.